Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

Rocchi, 2012, Inflammatory bowel disease: a Canadian burden of illness review, Can J Gastroenterol, 26, 811, 10.1155/2012/984575 Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 Kappelman, 2013, Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population, Dig Dis Sci, 58, 519, 10.1007/s10620-012-2371-5 Nguyen, 2007, Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004, Inflamm Bowel Dis, 13, 1529, 10.1002/ibd.20250 Kappelman, 2008, Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults, Gastroenterology, 135, 1907, 10.1053/j.gastro.2008.09.012 Render, 2011, 2011 Canadian Association of Gastroenterology educational needs assessment report, Can J Gastroenterol, 25, 244, 10.1155/2011/950476 Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, 6, 991, 10.1016/j.crohns.2012.09.002 Dignass, 2012, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis, J Crohns Colitis, 6, 965, 10.1016/j.crohns.2012.09.003 Bitton, 2012, Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements, Am J Gastroenterol, 107, 179, 10.1038/ajg.2011.386 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Dalkey, 1969, An experimental study of group opinion: the Delphi method, Futures, 1, 408, 10.1016/S0016-3287(69)80025-X Cook, 1997, The relation between systematic reviews and practice guidelines, Ann Intern Med, 127, 210, 10.7326/0003-4819-127-3-199708010-00006 Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE Satsangi, 2006, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, 55, 749, 10.1136/gut.2005.082909 Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603 Ardizzone, 2011, Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis, Clin Gastroenterol Hepatol, 9, 483, 10.1016/j.cgh.2010.12.028 Laharie, 2013, Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience, Aliment Pharmacol Ther, 37, 998, 10.1111/apt.12289 Colombel, 2011, Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis, Gastroenterology, 141, 1194, 10.1053/j.gastro.2011.06.054 D'Haens, 2007, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, 132, 763, 10.1053/j.gastro.2006.12.038 Schoepfer, 2013, Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes, Inflamm Bowel Dis, 19, 332, 10.1097/MIB.0b013e3182810066 Solberg, 2009, Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scand J Gastroenterol, 44, 431, 10.1080/00365520802600961 Ananthakrishnan, 2009, History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis, Inflamm Bowel Dis, 15, 176, 10.1002/ibd.20639 Langholz, 1996, Changes in extent of ulcerative colitis: a study on the course and prognostic factors, Scand J Gastroenterol, 31, 260, 10.3109/00365529609004876 Henriksen, 2008, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, 57, 1518, 10.1136/gut.2007.146357 Turner, 2007, Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression, Clin Gastroenterol Hepatol, 5, 103, 10.1016/j.cgh.2006.09.033 Hoie, 2007, Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort, Am J Gastroenterol, 102, 1692, 10.1111/j.1572-0241.2007.01265.x Ardizzone, 1995, Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study, J Clin Gastroenterol, 21, 287, 10.1097/00004836-199512000-00007 Fockens, 1995, Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group, Eur J Gastroenterol Hepatol, 7, 1025, 10.1097/00042737-199511000-00003 Faubion, 2001, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279 Marshall, 2010, Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD004115 Ford, 2012, Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 107, 167, 10.1038/ajg.2011.410 Marshall, 1995, Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis, Aliment Pharmacol Ther, 9, 293, 10.1111/j.1365-2036.1995.tb00384.x Marshall, 2000, Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis, Am J Gastroenterol, 95, 1628, 10.1111/j.1572-0241.2000.02180.x Bergman, 2006, Systematic review: the use of mesalazine in inflammatory bowel disease, Aliment Pharmacol Ther, 23, 841, 10.1111/j.1365-2036.2006.02846.x Cohen, 2000, A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis, Am J Gastroenterol, 95, 1263, 10.1111/j.1572-0241.2000.01940.x Manguso, 2007, Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis, Aliment Pharmacol Ther, 26, 21, 10.1111/j.1365-2036.2007.03349.x Gionchetti, 1998, Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis, Dis Colon Rectum, 41, 93, 10.1007/BF02236902 Watanabe, 2013, Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation—a placebo-controlled study, Aliment Pharmacol Ther, 38, 264, 10.1111/apt.12362 Ekbom, 1990, Ulcerative colitis and colorectal cancer. A population-based study, N Engl J Med, 323, 1228, 10.1056/NEJM199011013231802 van Bodegraven, 1996, Distribution of mesalazine enemas in active and quiescent ulcerative colitis, Aliment Pharmacol Ther, 10, 327, 10.1111/j.0953-0673.1996.00327.x Brown, 1997, Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy, Aliment Pharmacol Ther, 11, 685, 10.1046/j.1365-2036.1997.00193.x Eliakim, 2007, Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis, Aliment Pharmacol Ther, 26, 1237, 10.1111/j.1365-2036.2007.03468.x Feagan, 2012, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 10, CD000543 Ford, 2011, Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 106, 601, 10.1038/ajg.2011.67 Sandborn, 2009, Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis, Gastroenterology, 137, 1934, 10.1053/j.gastro.2009.08.069 Hanauer, 2007, Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial, Can J Gastroenterol, 21, 827, 10.1155/2007/862917 Hanauer, 2005, Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial, Am J Gastroenterol, 100, 2478, 10.1111/j.1572-0241.2005.00248.x Loftus, 2004, Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, Aliment Pharmacol Ther, 19, 179, 10.1111/j.0269-2813.2004.01827.x Gisbert, 2007, 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review, Inflamm Bowel Dis, 13, 629, 10.1002/ibd.20099 Pruitt, 2002, Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis, Am J Gastroenterol, 97, 3078, 10.1111/j.1572-0241.2002.07103.x Levine, 2002, A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis, Am J Gastroenterol, 97, 1398 Cortot, 2008, Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis, Am J Gastroenterol, 103, 3106, 10.1111/j.1572-0241.2008.02152.x Farup, 1995, Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens, Scand J Gastroenterol, 30, 164, 10.3109/00365529509093256 Hartmann, 2010, Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis, Aliment Pharmacol Ther, 32, 368, 10.1111/j.1365-2036.2010.04354.x Lemann, 1995, Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis, Aliment Pharmacol Ther, 9, 557, 10.1111/j.1365-2036.1995.tb00421.x Safdi, 1997, A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis, Am J Gastroenterol, 92, 1867 Kamm, 2009, Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis, Inflamm Bowel Dis, 15, 1, 10.1002/ibd.20580 Ford, 2012, Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis, Clin Gastroenterol Hepatol, 10, 513, 10.1016/j.cgh.2011.10.043 Marshall, 2012, Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 11, CD004118 Feagan, 2012, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 10, CD000544 Miner, 1995, Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group, Dig Dis Sci, 40, 296, 10.1007/BF02065413 Feagan, 2013, Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews, Inflamm Bowel Dis, 19, 2031 Feagan, 2012, Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis, Inflamm Bowel Dis, 18, 1785, 10.1002/ibd.23024 Flourie, 2013, Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis, Aliment Pharmacol Ther, 37, 767, 10.1111/apt.12266 Ford, 2011, Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis, Am J Gastroenterol, 106, 2070, 10.1038/ajg.2011.296 Dignass, 2009, Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis, Clin Gastroenterol Hepatol, 7, 762, 10.1016/j.cgh.2009.04.004 Kane, 2001, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, Am J Gastroenterol, 96, 2929, 10.1111/j.1572-0241.2001.04683.x Kane, 2003, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, Am J Med, 114, 39, 10.1016/S0002-9343(02)01383-9 Higgins, 2009, Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares, Aliment Pharmacol Ther, 29, 247, 10.1111/j.1365-2036.2008.03865.x Kane, 2008, Strategies to improve adherence and outcomes in patients with ulcerative colitis, Drugs, 68, 2601, 10.2165/0003495-200868180-00006 Kruis, 2009, Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial, Gut, 58, 233, 10.1136/gut.2008.154302 Sandborn, 2010, Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis, Gastroenterology, 138, 1286, 10.1053/j.gastro.2009.12.054 Ford, 2011, Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 590, 10.1038/ajg.2011.70 Campieri, 2003, Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study, Aliment Pharmacol Ther, 17, 1471, 10.1046/j.1365-2036.2003.01609.x Travis, 2014, Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study, Gut, 63, 433, 10.1136/gutjnl-2012-304258 Lichtenstein, 2006, American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology, 130, 940, 10.1053/j.gastro.2006.01.048 Dignass, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management, J Crohns Colitis, 4, 28, 10.1016/j.crohns.2009.12.002 Marshall, 1997, Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis, Gut, 40, 775, 10.1136/gut.40.6.775 1987, Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group, Dig Dis Sci, 32, 598, 10.1007/BF01296159 Lee, 1996, A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis, Gut, 38, 229, 10.1136/gut.38.2.229 Bar-Meir, 2003, Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis, Dis Colon Rectum, 46, 929, 10.1007/s10350-004-6687-x Sandborn, 2013, Efficacy and safety of budesonide foam for inducing remission in mildly to moderately active ulcerative proctitis or ulcerative proctosigmoiditis (abstr P-149), Inflamm Bowel Dis, 19, S83, 10.1097/01.MIB.0000438827.13410.d7 Powell-Tuck, 1981, A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission, Digestion, 22, 263, 10.1159/000198667 Lennard-Jones, 1965, Prednisone as maintenance treatment for ulcerative colitis in remission, Lancet, 1, 188, 10.1016/S0140-6736(65)90973-6 Truelove, 1959, Cortisone and corticotrophin in ulcerative colitis, Br Med J, 1, 387, 10.1136/bmj.1.5119.387 Bjarnason, 1997, Reduced bone density in patients with inflammatory bowel disease, Gut, 40, 228, 10.1136/gut.40.2.228 Lichtenstein, 2012, Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry, Am J Gastroenterol, 107, 1409, 10.1038/ajg.2012.218 Sandborn, 2012, Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study, Gastroenterology, 143, 1218, 10.1053/j.gastro.2012.08.003 D'Haens, 2010, Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis, J Crohns Colitis, 4, 153, 10.1016/j.crohns.2009.09.007 Lofberg, 1996, Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis, Gastroenterology, 110, 1713, 10.1053/gast.1996.v110.pm8964395 Gross, 2011, 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial, J Crohns Colitis, 5, 129, 10.1016/j.crohns.2010.11.006 Sherlock, 2010, Oral budesonide for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD007698 Schoon, 2005, Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease, Clin Gastroenterol Hepatol, 3, 113, 10.1016/S1542-3565(04)00662-7 Gisbert, 2009, Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis, Aliment Pharmacol Ther, 30, 126, 10.1111/j.1365-2036.2009.04023.x Jewell, 1974, Azathioprine in ulcerative colitis: final report on controlled therapeutic trial, Br Med J, 4, 627, 10.1136/bmj.4.5945.627 Sood, 2000, Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial, Indian J Gastroenterol, 19, 14 Khan, 2011, Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis, Am J Gastroenterol, 106, 630, 10.1038/ajg.2011.64 Ardizzone, 2006, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, 55, 47, 10.1136/gut.2005.068809 Timmer, 2012, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, 9, CD000478 Sood, 2002, The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis, J Gastroenterol, 37, 270, 10.1007/s005350200034 Hawthorne, 1992, Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, BMJ, 305, 20, 10.1136/bmj.305.6844.20 Kornbluth, 2010, Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee, Am J Gastroenterol, 105, 501, 10.1038/ajg.2009.727 Smith, 2010, Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease, Aliment Pharmacol Ther, 32, 119, 10.1111/j.1365-2036.2010.04330.x Kotlyar, 2011, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 9, 36, 10.1016/j.cgh.2010.09.016 Ariyaratnam, 2014, Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis, Am J Gastroenterol, 109, 163, 10.1038/ajg.2013.451 Health Canada. Imuran (azathioprine) or Purinethol (mercaptopurine) - association with a type of blood cancer - hepatosplenic T-cell lymphoma - for health professionals. Last Update 2014. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/38691a-eng.php. Accessed January 17, 2015. Marshall, 2014, Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease, Can J Gastroenterol Hepatol, 28, 371, 10.1155/2014/649465 Chande, 2007, Methotrexate for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD006618 El-Matary, 2009, Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, CD007560 Oren, 1996, Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial, Gastroenterology, 110, 1416, 10.1053/gast.1996.v110.pm8613046 Onuk, 1996, Low-dose weekly methotrexate therapy in remission maintenance in ulcerative colitis (abstr), Gut, 39, A75 Mate-Jimenez, 2000, 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease, Eur J Gastroenterol Hepatol, 12, 1227, 10.1097/00042737-200012110-00010 Egan, 1999, A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis, Aliment Pharmacol Ther, 13, 1597, 10.1046/j.1365-2036.1999.00667.x Manosa, 2011, Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy, J Crohns Colitis, 5, 397, 10.1016/j.crohns.2011.03.012 Khan, 2013, Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System, Inflamm Bowel Dis, 19, 1379, 10.1097/MIB.0b013e31828133e8 Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 644, 10.1038/ajg.2011.73 Lawson, 2006, Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD005112 Lv, 2014, Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis, PLoS One, 9, e86692, 10.1371/journal.pone.0086692 Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516 Reinisch, 2011, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, 60, 780, 10.1136/gut.2010.221127 Sandborn, 2012, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 257, 10.1053/j.gastro.2011.10.032 Sandborn, 2014, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 85, 10.1053/j.gastro.2013.05.048 Ford, 2013, Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials, Am J Gastroenterol, 108, 1268, 10.1038/ajg.2013.138 Targownik, 2013, Infectious and malignant complications of TNF inhibitor therapy in IBD, Am J Gastroenterol, 108, 1835, 10.1038/ajg.2013.294 Krieckaert, 2010, The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review, Arthritis Res Ther, 12, 217, 10.1186/ar3147 Pouw, 2013, Key findings towards optimising adalimumab treatment: the concentration-effect curve, Ann Rheum Dis, 74, 513, 10.1136/annrheumdis-2013-204172 Panaccione, 2014, Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, 146, 392, 10.1053/j.gastro.2013.10.052 Adedokun, 2013, Effects of immunomodulators on the pharmacokinetics and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from phase 2/3 PURSUIT-SC induction and maintenance studies (abstr), Am J Gastroenterol, 108, S517, 10.14309/00000434-201310001-01716 Lichtenstein, 2009, Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials, Aliment Pharmacol Ther, 30, 210, 10.1111/j.1365-2036.2009.04027.x Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Osterman, 2014, Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease, Gastroenterology, 146, 941, 10.1053/j.gastro.2013.12.025 Sandborn, 2014, Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 146, 96, 10.1053/j.gastro.2013.06.010 Reinisch, 2012, Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies, Inflamm Bowel Dis, 18, 201, 10.1002/ibd.21697 Sandborn, 2013, One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2, Aliment Pharmacol Ther, 37, 204, 10.1111/apt.12145 Reinisch, 2013, 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants, Inflamm Bowel Dis, 19, 1700, 10.1097/MIB.0b013e318281f2b7 Williams, 2014, Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease, Aliment Pharmacol Ther, 39, 447, 10.1111/apt.12624 Bewernitz, 2013, Assessment of adalimumab dose selection for adult ulcerative colitis using exposure-response analyses (abstr), J Pharmacokinet Pharmacodyn, 40, S44 Reinisch, 2012, Infliximab concentration and clinical outcome in patients with ulcerative colitis (abstr), Gastroenterology, 142, S-114, 10.1016/S0016-5085(12)60431-4 Roblin, 2014, Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol, 12, 80, 10.1016/j.cgh.2013.07.010 Hibi, 2012, Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease, Inflamm Bowel Dis, 18, 1480, 10.1002/ibd.21886 Vande Casteele, 2013, Antibody response to infliximab and its impact on pharmacokinetics can be transient, Am J Gastroenterol, 108, 962, 10.1038/ajg.2013.12 Afif, 2010, Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease, Am J Gastroenterol, 105, 1133, 10.1038/ajg.2010.9 Roblin, 2014, Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases, Am J Gastroenterol, 109, 1250, 10.1038/ajg.2014.146 Paul, 2013, Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study, Inflamm Bowel Dis, 19, 2568, 10.1097/MIB.0b013e3182a77b41 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734 Parikh, 2012, Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (abstr P-29), Inflamm Bowel Dis, 18, S26, 10.1097/00054725-201212001-00062 Parikh, 2012, Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study, Inflamm Bowel Dis, 18, 1470, 10.1002/ibd.21896 Parikh, 2013, Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease, Inflamm Bowel Dis, 19, 1691, 10.1097/MIB.0b013e318281f538 Feagan, 2009, Emerging safety profile of vedolizumab: A novel, selective integrin inhibitor for the treatment of IBD (abstr P-0025), Inflamm Bowel Dis, 15, S12, 10.1097/00054725-200912002-00033 Rosario, 2014, Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies (abstr DOP058), J Crohns Colitis, 8, S42, 10.1016/S1873-9946(14)60083-0 Moayyedi, 2014, Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy, Can J Gastroenterol Hepatol, 28, 66, 10.1155/2014/346590 Moayyedi, 2014, A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis (abstr 929c), Gastroenterology, 146, S-159, 10.1016/S0016-5085(14)60567-9 Shen, 2014, Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials, Inflamm Bowel Dis, 20, 21, 10.1097/01.MIB.0000437495.30052.be Mardini, 2014, Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis, Inflamm Bowel Dis, 20, 1562, 10.1097/MIB.0000000000000084 Petersen, 2014, Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial, J Crohns Colitis, 8, 1498, 10.1016/j.crohns.2014.06.001 Nikfar, 2010, Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis, Clin Ther, 32, 2304, 10.1016/j.clinthera.2011.01.004 Ogata, 2012, Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis, Inflamm Bowel Dis, 18, 803, 10.1002/ibd.21853 Lichtiger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 330, 1841, 10.1056/NEJM199406303302601 D'Haens, 2001, Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, Gastroenterology, 120, 1323, 10.1053/gast.2001.23983 Stremmel, 2007, Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial, Ann Intern Med, 147, 603, 10.7326/0003-4819-147-9-200711060-00004 Karner, 2014, First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses, Am J Gastroenterol, 109, 1041, 10.1038/ajg.2014.104 Stremmel, 2010, Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study, J Clin Gastroenterol, 44, e101, 10.1097/MCG.0b013e3181c29860 Summers, 2005, Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial, Gastroenterology, 128, 825, 10.1053/j.gastro.2005.01.005 Sandborn, 2012, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis, N Engl J Med, 367, 616, 10.1056/NEJMoa1112168 Higgins, 2014, The IBD drug pipeline-ready to deliver?, Am J Gastroenterol, 109, 1052, 10.1038/ajg.2014.179